Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Canonical NF-κB Pathway as a Central Regulator of Obesity-Associated Inflammation: A Narrative Review

Petrascu FM., Matei SC., Olteanu GE., Barna R., Marian C.

Narrative Review on Chronic Inflammation, published in Biomedicines (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biomedicines (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41463063
PMCID
PMC12730665
DOI
10.3390/biomedicines13123050
Citations
3

Abstract (original English)

Obesity is characterized by a chronic inflammation driven primarily by sustained activation of the canonical NF-κB signaling pathway. This persistent inflammatory state originates in hypertrophic adipose tissue and progressively affects multiple organ systems, contributing to systemic metabolic dysfunction. This review explores the molecular architecture and regulatory components of the canonical NF-κB pathway and outline how metabolic stressors, cytokines, chemokines, adhesion molecules, and dysregulated microRNAs influence its activity in obesity. Clinically relevant NF-κB linked biomarkers are characterized, those that reflect the degree of inflammation and may support risk stratification in metabolic disease. Finally, we discuss emerging therapeutic strategies, including small-molecule inhibitors, monoclonal antibodies, and miRNA-based approaches designed to modulate NF-κB activity while preserving its essential physiological roles. Together, these insights emphasize the central involvement of NF-κB in obesity-associated inflammation and highlight potential targets for selective intervention.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research